FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute

Liquidia Corporation (NASDAQ:LQDA) announced today that the U.S. Food and Drug Administration (FDA) has approved YUTREPIA (treprostinil) inhalation powder for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

YUTREPIA, enabled by Liquidia Corporation (NASDAQ:LQDA)’s proprietary PRINT technology, is the first and only prostacyclin dry-powder formulation designed for deep-lung delivery using a low-effort, portable inhalation device. The approval is based on results from the Phase 3 INSPIRE trial, which showed YUTREPIA to be safe and well-tolerated, offering a new treatment option for over 105,000 U.S. patients suffering from PAH and PH-ILD.

Liquidia Corporation (NASDAQ:LQDA)’s commercial team is preparing to launch YUTREPIA, aiming to improve exercise ability and quality of life for patients. However, United Therapeutics Corporation has filed a patent infringement lawsuit and is seeking a court order to block YUTREPIA’s commercial launch, with a decision on the injunction still pending.

While we acknowledge the potential of LQDA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than LQDA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.